Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.
acellular vaccines
live attenuated vaccines
outer membrane vesicles
pertussis
whole-cell vaccines
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
04
2021
accepted:
26
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Current vaccination strategies against pertussis are sub-optimal. Optimal protection against In this review we systematically analyzed published literature on protection conferred by mucosal immunization against pertussis. Immune responses mounted by these vaccines are summarized. The PubMed Library database was searched for published studies on mucosal pertussis vaccines. Eligibility criteria included mucosal administration and the evaluation of at least one outcome related to efficacy, immunogenicity and safety. While over 349 publications were identified by the search, only 63 studies met the eligibility criteria. All eligible studies are included here. Initial attempts of mucosal whole-cell vaccine administration in humans provided promising results, but were not followed up. More recently, diverse vaccination strategies have been tested, including non-replicating and replicating vaccine candidates given by three different mucosal routes: orally, nasally or rectally. Several adjuvants and particulate formulations were tested to enhance the efficacy of non-replicating vaccines administered mucosally. Most novel vaccine candidates were only tested in animal models, mainly mice. Only one novel mucosal vaccine candidate was tested in baboons and in human trials. Three vaccination strategies drew our attention, as they provided protective and durable immunity in the respiratory tract, including the upper respiratory tract: acellular vaccines adjuvanted with lipopeptide LP1569 and c-di-GMP, outer membrane vesicles and the live attenuated BPZE1 vaccine. Among all experimental vaccines, BPZE1 is the only one that has advanced into clinical development.
Sections du résumé
Background
Current vaccination strategies against pertussis are sub-optimal. Optimal protection against
Objectives
In this review we systematically analyzed published literature on protection conferred by mucosal immunization against pertussis. Immune responses mounted by these vaccines are summarized.
Method
The PubMed Library database was searched for published studies on mucosal pertussis vaccines. Eligibility criteria included mucosal administration and the evaluation of at least one outcome related to efficacy, immunogenicity and safety.
Results
While over 349 publications were identified by the search, only 63 studies met the eligibility criteria. All eligible studies are included here. Initial attempts of mucosal whole-cell vaccine administration in humans provided promising results, but were not followed up. More recently, diverse vaccination strategies have been tested, including non-replicating and replicating vaccine candidates given by three different mucosal routes: orally, nasally or rectally. Several adjuvants and particulate formulations were tested to enhance the efficacy of non-replicating vaccines administered mucosally. Most novel vaccine candidates were only tested in animal models, mainly mice. Only one novel mucosal vaccine candidate was tested in baboons and in human trials.
Conclusion
Three vaccination strategies drew our attention, as they provided protective and durable immunity in the respiratory tract, including the upper respiratory tract: acellular vaccines adjuvanted with lipopeptide LP1569 and c-di-GMP, outer membrane vesicles and the live attenuated BPZE1 vaccine. Among all experimental vaccines, BPZE1 is the only one that has advanced into clinical development.
Identifiants
pubmed: 34211481
doi: 10.3389/fimmu.2021.701285
pmc: PMC8239240
doi:
Substances chimiques
Pertussis Vaccine
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
701285Informations de copyright
Copyright © 2021 Dubois and Locht.
Déclaration de conflit d'intérêts
CL is listed as inventor of patents concerning the live attenuated BPZE1 vaccine. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Pathog. 2013;9(4):e1003264
pubmed: 23592988
Curr Microbiol. 1999 May;38(5):273-8
pubmed: 10355115
Clin Vaccine Immunol. 2010 Mar;17(3):317-24
pubmed: 20107007
Infect Immun. 1990 Aug;58(8):2523-8
pubmed: 2370105
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
Vaccine. 2000 May 8;18(22):2323-30
pubmed: 10738087
Nat Biotechnol. 1998 May;16(5):454-7
pubmed: 9592394
Clin Vaccine Immunol. 2014 Feb;21(2):119-25
pubmed: 24256623
Mol Cell Proteomics. 2018 Feb;17(2):205-215
pubmed: 29203497
Infect Immun. 1990 Mar;58(3):732-9
pubmed: 2407655
Mucosal Immunol. 2013 Jul;6(4):787-96
pubmed: 23187316
Vaccine. 2007 Jan 2;25(1):64-71
pubmed: 16916566
Science. 1982 Feb 26;215(4536):1053-60
pubmed: 7063839
Vaccine. 1993;11(8):866-72
pubmed: 8356847
Vaccines (Basel). 2020 Sep 13;8(3):
pubmed: 32933132
Clin Vaccine Immunol. 2009 Sep;16(9):1344-51
pubmed: 19625486
J Clin Invest. 2020 May 1;130(5):2332-2346
pubmed: 31945015
Lancet. 1997 Nov 29;350(9091):1569-77
pubmed: 9393335
PLoS One. 2014 Aug 19;9(8):e104548
pubmed: 25137043
Infect Immun. 2021 Feb 16;89(3):
pubmed: 33318136
Infect Immun. 2003 Apr;71(4):2272-5
pubmed: 12654855
Vaccine. 2014 Jun 5;32(27):3350-6
pubmed: 24793938
PLoS One. 2014 Jan 08;9(1):e83449
pubmed: 24421886
Vaccines (Basel). 2020 Nov 03;8(4):
pubmed: 33153066
Emerg Microbes Infect. 2019;8(1):169-185
pubmed: 30866771
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Vaccine. 1997 Aug-Sep;15(12-13):1473-8
pubmed: 9302763
J Infect Dis. 2017 Jul 1;216(1):117-124
pubmed: 28535276
Vaccine. 2010 Mar 8;28(11):2311-7
pubmed: 20060944
Vaccine. 2003 Mar 7;21(11-12):1165-73
pubmed: 12559794
Infect Immun. 2000 Feb;68(2):485-91
pubmed: 10639408
Front Immunol. 2019 Jan 14;9:3068
pubmed: 30692990
Immunol Lett. 2018 Jun;198:26-32
pubmed: 29601940
Sci Adv. 2020 Feb 05;6(6):eaay9258
pubmed: 32076653
Infect Immun. 1999 Dec;67(12):6270-80
pubmed: 10569737
Vaccine. 1998 Mar;16(5):522-9
pubmed: 9491507
Infect Immun. 1996 Oct;64(10):4172-81
pubmed: 8926085
Infect Immun. 1996 Feb;64(2):489-94
pubmed: 8550197
J Immunol. 2000 Nov 1;165(9):4778-82
pubmed: 11045998
J Microbiol Biotechnol. 2012 Jun;22(6):856-65
pubmed: 22573165
Microb Pathog. 1993 Feb;14(2):149-60
pubmed: 8502163
Vaccine. 2008 Oct 23;26(45):5722-7
pubmed: 18762220
Biomed Res Int. 2014;2014:421486
pubmed: 24982881
Microb Pathog. 2018 Jul;120:155-160
pubmed: 29738814
Lancet. 1991 Nov 16;338(8777):1230-3
pubmed: 1682643
Can J Microbiol. 2006 May;52(5):436-44
pubmed: 16699568
J Immunol. 2003 Feb 1;170(3):1504-9
pubmed: 12538714
J Hyg (Lond). 1975 Apr;74(2):233-7
pubmed: 164502
Vaccine. 2014 Jul 23;32(34):4281-8
pubmed: 24950361
Vaccine. 2021 May 18;39(21):2843-2849
pubmed: 33896662
Clin Vaccine Immunol. 2011 Feb;18(2):187-93
pubmed: 21147936
Front Immunol. 2018 Dec 07;9:2872
pubmed: 30581436
J Infect. 2016 Jul 5;72 Suppl:S34-40
pubmed: 27161992
Infect Immun. 1991 Dec;59(12):4391-7
pubmed: 1937797
Dev Biol Stand. 1985;61:511-6
pubmed: 2872129
Infect Immun. 1995 Apr;63(4):1195-200
pubmed: 7890372
PLoS Pathog. 2006 Jul;2(7):e65
pubmed: 16839199
Int J Biol Macromol. 2018 Feb;107(Pt B):2044-2056
pubmed: 29037872
BMC Med. 2015 Jun 24;13:146
pubmed: 26103968
Vaccine. 2018 Mar 7;36(11):1345-1352
pubmed: 29433898
Lancet. 1984 Jan 21;1(8369):122-6
pubmed: 6140441
Mucosal Immunol. 2018 Nov;11(6):1763-1776
pubmed: 30127384
Vaccine. 1996 Oct;14(14):1384-90
pubmed: 9004450
J Control Release. 2018 Sep 28;286:167-178
pubmed: 30048656
Infect Immun. 1998 Apr;66(4):1648-53
pubmed: 9529093
J Immunol. 2019 Dec 15;203(12):3293-3300
pubmed: 31732529
FEMS Microbiol Lett. 2002 Mar 5;208(2):175-8
pubmed: 11959433
Vaccines (Basel). 2020 Nov 19;8(4):
pubmed: 33228165
Vaccine. 2001 Feb 28;19(15-16):1940-50
pubmed: 11228364
Vaccine. 2011 Feb 11;29(8):1649-56
pubmed: 21211579
Am J Vet Res. 1981 Jul;42(7):1130-2
pubmed: 7271029
Vaccine. 2008 Aug 26;26(36):4639-46
pubmed: 18640169
Clin Infect Dis. 2020 Jul 11;71(2):412-414
pubmed: 31552410
Vet Res. 2005 Jan-Feb;36(1):63-77
pubmed: 15610724
Vaccine. 1998 Dec;16(20):2039-46
pubmed: 9796062
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S58-61
pubmed: 15876927
PLoS One. 2010 Apr 15;5(4):e10178
pubmed: 20419113
J Infect. 2006 Jan;52(1):e11-3
pubmed: 15936087
Vaccines (Basel). 2020 Jul 30;8(3):
pubmed: 32751680
Sci Rep. 2020 Apr 30;10(1):7396
pubmed: 32355188
J Med Microbiol. 2000 Feb;49(2):157-163
pubmed: 10670566
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):787-92
pubmed: 24277828
Infect Immun. 1992 Oct;60(10):4260-8
pubmed: 1398937
Clin Microbiol Infect. 2019 Dec;25(12):1457-1458
pubmed: 31158520
Mucosal Immunol. 2018 May;11(3):1009
pubmed: 29411776
J Clin Microbiol. 1994 Nov;32(11):2851-3
pubmed: 7852585
Infect Immun. 2010 May;78(5):2008-16
pubmed: 20176797
J Exp Med. 1997 Dec 1;186(11):1843-51
pubmed: 9382883
Lancet Infect Dis. 2020 Nov;20(11):1290-1301
pubmed: 32687804
Mucosal Immunol. 2018 Nov;11(6):1753-1762
pubmed: 30115992
Vaccine. 2001 Sep 14;19(32):4824-34
pubmed: 11535335
Hum Vaccin Immunother. 2013 Feb;9(2):325-31
pubmed: 23291942
Vaccine. 2010 Oct 8;28(43):7047-53
pubmed: 20708998
NPJ Vaccines. 2019 Oct 3;4:40
pubmed: 31602318
NPJ Vaccines. 2021 Jan 8;6(1):6
pubmed: 33420041
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2605-2611
pubmed: 31240957
Infect Immun. 2007 Jul;75(7):3665-72
pubmed: 17452472
Vaccine. 2004 Sep 9;22(27-28):3595-602
pubmed: 15315838